Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

ImmunoPrecise Antibodies Ltd. (V:IPA)

Business Focus: Biopharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEDAR
Company Contact
Address: 880 - 580 HORNBY STREET
Tel: N/A
IR: See website
Key People
Jennifer Lynne Bath
President, Chief Executive Officer, Director
Lisa Helbling
Chief Financial Officer
Ilse Roodink
Chief Scientific Officer
Carla Dahl
Vice President of Marketing
Barry Duplantis
Vice President - Client Relations
Stefan Lang
Chief Business Officer
Business Overview
ImmunoPrecise Antibodies Ltd. is a technology platform company that is engaged in the full-service therapeutic antibody discovery. The Company is focused on offering species-agnostic advancements, such as the B cell Select single-cell interrogation technology, DeepDisplay custom phage libraries, as well as the Abthena bispecific program. Its geographical segments include United States of America, Canada and Europe. The Company's Antibody Discovery offers design, immunization, characterization and optimization, and preclinical services. The Company offers mammalian protein expression and purification services as stand-alone or in combination after an antibody discovery project to produce the number of antibodies that need for further work. Its mammalian rPEx platform allows the production of all kinds of proteins, including difficult-to-express proteins, Fc-fusion proteins and bispecific antibodies.
Financial Overview
For the three months ended 31 July 2021,Immunoprecise Antibodies Ltd revenues increased 22% toC$4.6M. Net loss increased from C$549K to C$3.2M. Revenuesreflect Project revenue segment increase of 24% to C$4.3M,Cryo storage revenue segment increase from C$4K to C$15K,Europe segment increase of 58% to C$2M, United States ofAmerica segment increase of 10% to C$1.9M.
Reporting Currency: Canadian Dollars
Enterprise value: $97.32M as of Jul 31, 2021
Annual revenue (TTM): $18.74M as of Jul 31, 2021
EBITDA (TTM): -$5.75M as of Jul 31, 2021
Net annual income (TTM): -$10.02M as of Jul 31, 2021
Free cash flow (TTM): -$3.66M as of Jul 31, 2021
Net Debt Last Fiscal Year: N/A
Shares outstanding: 19,374,690 as of Nov 12, 2021
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization